R&D
Why the government’s latest funding push is critical to the ...
Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa
News
Gilead buys cell therapy partner Arcellx for up to $7.8bn
Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.
News
Head-to-head trial dents Novo Nordisk's obesity hopes
Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.
R&D
Navigating development in a complex molecule world
For decades, the pharmaceutical industry has relied on accelerated development and manufacturing timelines to bring new therapies to patients quickly.
News
Grail's multi-cancer test fluffs its lines in UK trial
Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
